MediLexicon News - NPS RADAR Reviews Rivaroxaban - Oral Anticoagulant For Post-knee Replacement Surgery, Australia

news headlines

email to a friend

printer friendly

NPS RADAR Reviews Rivaroxaban - Oral Anticoagulant For Post-knee Replacement Surgery, Australia

Main Category: Bones / Orthopaedics
Also Included In: Blood / Hematology | Pharmacy / Pharmacist
Article Date: 31 Jul 2009

Prescribers treating patients who have had total hip or knee replacement surgery can access an independent review of the oral anticoagulant rivaroxaban (Xarelto) in the August issue of NPS RADAR.

NPS RADAR provides independent information about new medicines and changes to PBS listings to health professionals and is published to coincide with PBS updates, giving health professionals access to information when they need it.

"GPs and pharmacists may see patients who have been initiated on rivaroxaban in hospital. They should be aware that rivaroxaban has only been evaluated for use in preventing deep vein thrombosis and pulmonary embolism after elective total hip or total knee replacement surgery," NPS senior adviser, quality use of medicines, Judith Mackson said.

"Duration of the therapy is 14 days after knee replacement or 35 days after hip replacement and no longer. Some patients will need a GP prescription soon after discharge to cover the remaining duration of therapy. GPs will need to take into account the number of tablets the hospital has provided when selecting a suitable pack size and instructing the patient on how many tablets to take."

Dose adjustment and titration, and monitoring of prothrombin time are not required. As with other anticoagulants, managing the risk of bleeding is a primary concern, and patients should be alert to possible signs of bleeding.

"Prescribers should be aware that there are only small differences in efficacy and safety between rivaroxaban, low molecular weight heparins (Clexane and Fragmin), fondaparinux (Arixtra) and dabigatran (Pradaxa)," Ms Mackson said.

Other topics covered in the latest edition of NPS RADAR include:

- Hydromorphone prolonged-release tablets (Jurnista) for chronic severe disabling pain
- Oxybutynin patch (Oxytrol) PBS listed as an alternative for overactive bladder
- Update on PBS listings for Aboriginal peoples and Torres Strait Islanders
- Sitagliptin with metformin
- (Janumet) fixed-dose combination tablets PBS listed for type 2 diabetes mellitus
- Risedronate (Actonel Once-a-month) and summary of anti-resorptive drug listings
- Lanthanum (Fosrenol) tablets for adults with chronic kidney disease who are on dialysis

http://www.nps.org.au/radar

Source
National Prescribing Service.

Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today

Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles.

< back to medical news

For any corrections of factual information, or to contact the editors please use our feedback form.

Send your press releases to

NPS RADAR Reviews Rivaroxaban - Oral Anticoagulant For Post-knee Replacement Surgery, Australia

PDA Medical Dictionary